10x Genomics Reports First Quarter 2026 Financial Results
Rhea-AI Summary
10x Genomics (Nasdaq: TXG) reported Q1 2026 revenue of $150.8 million, a 3% decrease year-over-year; excluding a $16.8 million 2025 one-time patent settlement, revenue rose 9%. Gross margin was 70%. Operating loss was $17.0 million and net loss $13.5 million. Cash and marketable securities totaled $539.8 million, up $112.9 million year-over-year. The company launched Atera, expects shipments in H2 2026, announced a Bioptimus partnership for the STELA initiative, and reaffirmed full-year 2026 revenue guidance of $600–$625 million.
AI-generated analysis. Not financial advice.
Positive
- Revenue excluding 2025 settlement +9% year-over-year
- Gross margin improved to 70%
- Operating expenses decreased by 15%
- Cash and marketable securities increased by $112.9 million
- Launched Atera platform; shipping expected H2 2026
Negative
- Reported revenue declined 3% to $150.8 million
- Operating loss of $17.0 million
- Net loss of $13.5 million
- Full-year 2026 guidance implies modest growth of 0%–4% excluding one-time 2025 items
Key Figures
Market Reality Check
Peers on Argus
TXG gained 3.32% with modestly elevated volume. Peers were mixed: CERT up 1.95%, SDGR up 6.49%, while PHR slipped 0.42% and OMCL/GDRX were flat, pointing to a stock-specific reaction to earnings.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Q4/FY25 earnings | Positive | +3.5% | Reported FY2025 results with narrowed losses and initiated 2026 revenue guidance. |
| Jan 11 | Preliminary Q4/FY25 | Negative | -3.2% | Preliminary 2025 results showed weak instruments revenue and adjusted revenue decline. |
| Nov 06 | Q3 2025 earnings | Negative | +17.3% | Q3 results with lower gross margin and guidance implying year-over-year revenue decline. |
| Aug 07 | Q2 2025 earnings | Positive | -4.0% | Q2 revenue aided by litigation gain, improved margins and a return to net income. |
| May 08 | Q1 2025 earnings | Negative | +1.6% | Mixed Q1 results with workforce reductions and withdrawn full-year guidance amid funding uncertainty. |
Earnings releases often narrow losses and maintain guidance, but price reactions have been mixed, with several instances of shares rising despite cautious or negative elements in the results.
Over the past year, 10x Genomics has reported a series of earnings showing modest revenue pressure but improving profitability. Prior quarters highlighted litigation-related revenue, restructuring actions, margin improvements, and narrowing operating and net losses, with cash balances above $447M. The current Q1 2026 report continues this pattern: revenue of $150.8M is down 3% year-over-year but up 9% excluding one-time 2025 items, gross margin improved to 70%, operating expenses fell, and net loss narrowed further, while 2026 revenue guidance of $600M–$625M is maintained.
Historical Comparison
Historically, TXG earnings headlines moved the stock an average of 3.04%. Today’s 3.32% gain sits close to that norm, suggesting a typical-sized reaction to modest revenue pressure but improving margins and losses.
Earnings updates over 2025–2026 show a shift from litigation-boosted revenue and restructuring toward steadier core growth, higher gross margins, and consistently narrowing operating and net losses.
Market Pulse Summary
This announcement delivered Q1 2026 revenue of $150.8M, down 3% year-over-year but up 9% when excluding prior one-time license and royalty revenue. Profitability metrics improved, with gross margin at 70%, operating expenses reduced to $123.2M, and net loss narrowing to $13.5M. Cash and marketable securities reached $539.8M, and full-year 2026 revenue guidance of $600M–$625M was maintained. Investors may watch Atera’s rollout, core consumables growth, and expense discipline in coming quarters.
Key Terms
spatial biology medical
whole-transcriptome analysis medical
single-cell sensitivity medical
AI-generated analysis. Not financial advice.
Recent Updates
- Revenue was
$150.8 million 3% decrease over the corresponding period of 2025. Excluding$16 9% over the corresponding period of 2025. - Launched Atera, a new platform to redefine how biology is measured and understood. Atera was engineered to deliver spatial whole-transcriptome analysis with single-cell sensitivity at unprecedented scale. The Company expects to start shipping Atera in the second half of 2026.
- Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes. The initiative is starting this effort on our Xenium platform and plans to expand to Atera over time.
- Ended the first quarter of 2026 with cash and cash equivalents and marketable securities of
$539.8 million $112.9 million
"We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response."
First Quarter 2026 Financial Results
Revenue was
Gross margin was
Operating expenses were
Operating loss was
Net loss was
Cash and cash equivalents and marketable securities were
2026 Financial Guidance
10x Genomics is maintaining its full year 2026 revenue guidance of
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the first quarter 2026 financial results, business developments and outlook after market close on Thursday, May 7, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s products, services, business strategy, collaborations and opportunities and 10x Genomics, Inc.'s financial performance and results of operations, including expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
10x Genomics, Inc. | |||
Condensed Consolidated Statements of Operations | |||
(Unaudited) | |||
(In thousands, except share and per share data) | |||
Three Months Ended | |||
2026 | 2025 | ||
Products and services revenue | $ 149,896 | $ 137,823 | |
License and royalty revenue | 947 | 17,060 | |
Revenue (1) | 150,843 | 154,883 | |
Cost of products and services revenue (2) | 44,665 | 49,438 | |
Gross profit | 106,178 | 105,445 | |
Operating expenses: | |||
Research and development (2) | 56,847 | 64,245 | |
Selling, general and administrative (2) | 66,377 | 89,728 | |
Gain on settlement | — | (9,200) | |
Total operating expenses | 123,224 | 144,773 | |
Loss from operations | (17,046) | (39,328) | |
Other income (expense): | |||
Interest income | 5,014 | 3,686 | |
Other income (expense), net | (815) | 2,136 | |
Total other income | 4,199 | 5,822 | |
Loss before provision for income taxes | (12,847) | (33,506) | |
Provision for income taxes | 623 | 852 | |
Net loss | $ (13,470) | $ (34,358) | |
Net loss per share, basic and diluted | $ (0.10) | $ (0.28) | |
Weighted-average shares used to compute net loss per share, basic and diluted | 128,291,153 | 122,606,091 | |
__________________________ | |
(1) | The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium and Xenium products: |
Three Months Ended | |||
2026 | 2025 | ||
Instruments | |||
Single Cell | $ 5,223 | $ 5,913 | |
Spatial | 6,039 | 8,902 | |
Total instruments revenue | 11,262 | 14,815 | |
Consumables | |||
Single Cell | 88,894 | 84,109 | |
Spatial | 40,907 | 31,247 | |
Total consumables revenue | 129,801 | 115,356 | |
Services | 8,833 | 7,652 | |
Products and services revenue | 149,896 | 137,823 | |
License and royalty revenue | 947 | 17,060 | |
Total revenue | $ 150,843 | $ 154,883 | |
(1) | The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): |
Three Months Ended | |||
2026 | 2025 | ||
$ 76,693 | $ 86,818 | ||
3,406 | 3,752 | ||
Total | 80,099 | 90,570 | |
36,852 | 31,895 | ||
15,837 | 16,883 | ||
18,055 | 15,535 | ||
Total | 33,892 | 32,418 | |
Total revenue | $ 150,843 | $ 154,883 | |
* | Includes license and royalty revenue. |
(2) | Includes stock-based compensation expense as follows: |
Three Months Ended | |||
(in thousands) | 2026 | 2025 | |
Cost of revenue | $ 1,918 | $ 2,481 | |
Research and development | 10,695 | 14,106 | |
Selling, general and administrative | 10,029 | 14,489 | |
Total stock-based compensation expense | $ 22,642 | $ 31,076 | |
10x Genomics, Inc. | |||
Condensed Consolidated Balance Sheets | |||
(Unaudited) | |||
(In thousands) | |||
March 31, | December 31, | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 490,285 | $ 473,966 | |
Marketable securities | 49,563 | 49,443 | |
Accounts receivable, net | 39,031 | 47,013 | |
Other receivables | 17,106 | 35,480 | |
Inventory | 53,487 | 56,341 | |
Prepaid expenses and other current assets | 20,261 | 22,208 | |
Total current assets | 669,733 | 684,451 | |
Property and equipment, net | 220,591 | 226,711 | |
Operating lease right-of-use assets | 58,390 | 60,450 | |
Goodwill | 4,511 | 4,511 | |
Intangible assets, net | 59,910 | 62,329 | |
Other noncurrent assets | 2,624 | 2,913 | |
Total assets | $ 1,015,759 | $ 1,041,365 | |
Liabilities and stockholders' equity | |||
Current liabilities: | |||
Accounts payable | $ 17,425 | $ 12,733 | |
Accrued compensation and related benefits | 21,506 | 42,500 | |
Accrued expenses and other current liabilities | 33,680 | 39,971 | |
Deferred revenue | 24,342 | 23,902 | |
Operating lease liabilities | 11,330 | 10,985 | |
Contingent consideration, current | 5,315 | 23,363 | |
Total current liabilities | 113,598 | 153,454 | |
Contingent consideration, noncurrent | 1,222 | 1,237 | |
Operating lease liabilities, noncurrent | 70,059 | 73,376 | |
Deferred revenue, noncurrent | 10,138 | 10,501 | |
Other noncurrent liabilities | 6,418 | 6,471 | |
Total liabilities | 201,435 | 245,039 | |
Commitments and contingencies | |||
Stockholders' equity: | |||
Preferred stock | — | — | |
Common stock | 2 | 2 | |
Additional paid-in capital | 2,338,269 | 2,306,690 | |
Accumulated deficit | (1,524,061) | (1,510,591) | |
Accumulated other comprehensive income | 114 | 225 | |
Total stockholders' equity | 814,324 | 796,326 | |
Total liabilities and stockholders' equity | $ 1,015,759 | $ 1,041,365 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-first-quarter-2026-financial-results-302766095.html
SOURCE 10x Genomics, Inc.